Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) FCF Margin (2016 - 2025)

Historic FCF Margin for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to 33.05%.

  • Ptc Therapeutics' FCF Margin rose 63400.0% to 33.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 39.64%, marking a year-over-year increase of 657300.0%. This contributed to the annual value of 14.15% for FY2024, which is 57700.0% up from last year.
  • As of Q3 2025, Ptc Therapeutics' FCF Margin stood at 33.05%, which was up 63400.0% from 33.35% recorded in Q2 2025.
  • Ptc Therapeutics' 5-year FCF Margin high stood at 73.84% for Q1 2025, and its period low was 104.28% during Q4 2022.
  • Moreover, its 5-year median value for FCF Margin was 33.44% (2021), whereas its average is 29.85%.
  • Per our database at Business Quant, Ptc Therapeutics' FCF Margin tumbled by -608300bps in 2021 and then skyrocketed by 698100bps in 2023.
  • Ptc Therapeutics' FCF Margin (Quarter) stood at 46.94% in 2021, then plummeted by -122bps to 104.28% in 2022, then skyrocketed by 67bps to 34.47% in 2023, then soared by 54bps to 15.84% in 2024, then crashed by -109bps to 33.05% in 2025.
  • Its last three reported values are 33.05% in Q3 2025, 33.35% for Q2 2025, and 73.84% during Q1 2025.